군발두통 치료 시장 : 전략적 인사이트와 예측(2026-2035년)

The Global Cluster Headache Treatment Landscape Report is expected to grow from USD 5.31 billion in 2026 at a 6.1% CAGR to USD 9.01 billion in 2035.

Cluster headache is a rare but highly debilitating neurological disorder characterized by recurrent episodes of severe unilateral headache accompanied by autonomic symptoms. Treatment strategies include acute therapies for immediate pain relief, preventive therapies that reduce attack frequency, and bridge therapies that provide temporary symptom control while preventive medications become effective. Advances in targeted biologics, device-based therapies, and precision neurology are transforming disease management and improving long-term patient outcomes.

Market Drivers

Growing Disease Awareness and Earlier Diagnosis

Improved physician education, updated clinical guidelines, and greater awareness among patients are increasing diagnosis rates and referrals to specialist headache clinics. Earlier diagnosis enables timely initiation of preventive therapies and expands the addressable treatment population.

Expansion of CGRP-Targeted Therapies

The introduction of CGRP monoclonal antibodies has significantly advanced preventive treatment options for cluster headache. These targeted therapies provide improved disease control by addressing underlying neuropeptide pathways involved in headache pathophysiology.

Increasing Adoption of Neuromodulation

Non-invasive neuromodulation devices are gaining acceptance as effective treatment options for patients with inadequate response or intolerance to conventional medications. Portable home-use devices are improving treatment convenience and supporting long-term disease management.

Rising Investment in Rare Neurological Disorders

Regulatory incentives for orphan diseases, expanding neurological research, and increased pharmaceutical investment are accelerating pipeline development and commercialization of innovative cluster headache therapies.

Market Restraints

Limited Approved Preventive Therapies

Although treatment options continue to expand, the number of approved preventive therapies remains limited, leaving substantial unmet clinical needs for many patients.

Small Patient Population

The rarity of cluster headache reduces commercial attractiveness compared with more prevalent neurological disorders and may limit investment in late-stage clinical development.

High Cost of Innovative Therapies

Biologics and advanced neuromodulation devices remain expensive, creating reimbursement challenges and limiting access in several healthcare systems.

Treatment and Technology Insights

The global cluster headache treatment market can be segmented by treatment type, drug class, indication, route of administration, end user, distribution channel, and geography.

By treatment type, the market includes acute treatment, preventive treatment, and bridge treatment. Acute therapies remain the cornerstone of disease management because patients require immediate symptom relief during attacks. Preventive therapies are experiencing the fastest growth as clinicians increasingly focus on reducing attack frequency and improving long-term disease control. Bridge therapies continue to provide temporary symptom management during initiation of preventive treatment.

By drug class, the market comprises triptans, CGRP monoclonal antibodies, calcium channel blockers, corticosteroids, and other drug classes. Triptans remain the standard acute treatment, while CGRP-targeted therapies represent the fastest-growing segment because of their targeted mechanism of action and improved preventive efficacy. Verapamil continues to serve as the most widely used preventive therapy, with corticosteroids commonly utilized as bridge treatment.

By indication, the market includes episodic cluster headache and chronic cluster headache. Episodic disease accounts for the majority of treated patients, while chronic cluster headache continues to generate significant demand for innovative preventive therapies because of its persistent disease burden.

By route of administration, treatments are available as oral, injectable, and intranasal formulations. Injectable therapies continue to play a major role because of their rapid onset during acute attacks, while oral preventive medications remain widely prescribed.

By end user, the market includes hospitals, specialty clinics, and home care settings. Specialty headache centers are increasingly adopting biologics and neuromodulation technologies, while home care continues to expand through self-administered therapies and portable treatment devices.

Technological advances including digital headache monitoring, wearable devices, artificial intelligence-assisted diagnosis, remote patient management, and neuromodulation platforms are improving disease management and supporting personalized treatment strategies.

Market Trends

The cluster headache treatment landscape continues to evolve toward personalized and mechanism-based therapies.

Key trends include:

• Growing adoption of CGRP-targeted biologics.
• Increasing utilization of neuromodulation technologies.
• Expansion of specialist headache centers.
• Rising use of home-based treatment devices.
• Greater investment in precision neurology.
• Improved integration of digital health and remote patient monitoring.
• Increasing development of targeted preventive therapies.

Regional Insights

North America dominates the global cluster headache treatment market because of advanced neurological care infrastructure, high diagnosis rates, favorable reimbursement systems, and rapid adoption of innovative biologics and neuromodulation devices. The United States remains the leading contributor to research, clinical trials, and commercialization activities.

Europe maintains a significant market share through established treatment guidelines, universal healthcare systems, and increasing adoption of evidence-based preventive therapies. Careful reimbursement evaluation continues to influence biologic adoption across European countries.

Asia-Pacific is expected to register the fastest market growth owing to improving diagnosis, expanding healthcare expenditure, increasing awareness of rare neurological disorders, and strengthening specialist neurology services across China, Japan, South Korea, India, and Australia.

Latin America and the Middle East & Africa continue to improve access to neurological care through healthcare modernization, although conventional pharmacological therapies remain the primary treatment approach in many countries.

Competitive Landscape

The cluster headache treatment market includes multinational pharmaceutical companies, biotechnology companies, medical device manufacturers, and specialty neurology developers.

Companies continue investing in CGRP monoclonal antibodies, neuromodulation devices, targeted biologics, precision medicine, and digital healthcare technologies. Strategic collaborations, licensing agreements, mergers and acquisitions, and orphan disease development programs remain important competitive strategies for strengthening market presence and accelerating innovation.

Future Outlook

The future of the cluster headache treatment market will be driven by advances in precision neurology, targeted biologics, neuromodulation technologies, and personalized medicine. Continued research into CGRP biology, neuropeptide modulation, wearable monitoring, and artificial intelligence-assisted diagnosis is expected to improve disease management and support broader adoption of innovative therapies.

Expansion of real-world evidence, digital health platforms, and patient-centered treatment approaches is expected to improve long-term outcomes while creating new commercial opportunities through 2035.

Conclusion

The global Cluster Headache Treatment Market is expected to demonstrate steady growth through 2035, supported by increasing disease awareness, expanding adoption of preventive therapies, continued innovation in CGRP-targeted biologics, and growing use of neuromodulation technologies. Although challenges related to limited approved therapies, reimbursement constraints, and the rarity of the disease remain, ongoing advances in neuroscience, precision medicine, and digital healthcare are expected to significantly improve patient outcomes and create new opportunities for pharmaceutical companies, biotechnology firms, healthcare providers, and investors.

Key Benefits of this Report

• Comprehensive analysis of the global cluster headache treatment market and future growth opportunities.
• Detailed evaluation of treatment modalities, therapeutic innovations, and emerging technology trends.
• Competitive assessment of leading companies, pipeline developments, and strategic initiatives.
• Insights into market drivers, restraints, regulatory trends, and commercialization opportunities.
• Valuable resource for pharmaceutical companies, biotechnology firms, medical device manufacturers, healthcare providers, researchers, investors, consultants, and policymakers.

What Businesses Use Our Reports For

Market forecasting, competitive intelligence, pipeline assessment, portfolio optimization, licensing and partnership evaluation, commercialization planning, regulatory strategy development, investment analysis, and identification of emerging business opportunities.

Report Coverage

• Historical data from 2021 to 2024, Base Year 2025, and Forecast Period 2026 to 2035
• Comprehensive analysis of the global cluster headache treatment market by treatment type, drug class, indication, route of administration, end user, distribution channel, and geography
• Evaluation of market size, growth drivers, restraints, treatment landscape, competitive dynamics, and emerging technology trends
• Assessment of regulatory developments, reimbursement landscape, strategic collaborations, licensing activities, mergers and acquisitions, and commercialization strategies
• Analysis of acute therapies, preventive therapies, bridge therapies, CGRP monoclonal antibodies, neuromodulation technologies, precision neurology, and future market opportunities through 2035.

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Epidemiology Highlights
• 1.4 Commercial Landscape Overview
• 1.5 Pipeline and Innovation Highlights
• 1.6 Key Growth Opportunities
• 1.7 Future Outlook

2. Disease & Epidemiology Analysis

• 2.1 Introduction to Cluster Headache
  • 2.1.1 Disease Definition
  • 2.1.2 Disease Burden and Unmet Needs
  • 2.1.3 Clinical Presentation and Symptoms
• 2.2 Disease Classification
  • 2.2.1 Episodic Cluster Headache
  • 2.2.2 Chronic Cluster Headache
• 2.3 Etiology and Risk Factors
  • 2.3.1 Genetic Factors
  • 2.3.2 Neurovascular Mechanisms
  • 2.3.3 Environmental and Lifestyle Factors
• 2.4 Disease Pathophysiology
  • 2.4.1 Hypothalamic Dysfunction
  • 2.4.2 Trigeminal Autonomic Reflex Activation
  • 2.4.3 Calcitonin Gene-Related Peptide (CGRP) Pathway
  • 2.4.4 Other Emerging Molecular Pathways
• 2.5 Diagnosis and Clinical Assessment
  • 2.5.1 Diagnostic Criteria
  • 2.5.2 Differential Diagnosis
  • 2.5.3 Imaging and Diagnostic Procedures
  • 2.5.4 Patient Journey and Time to Diagnosis
• 2.6 Epidemiology Analysis
  • 2.6.1 Global Prevalence
  • 2.6.2 Global Incidence
  • 2.6.3 Epidemiology by Disease Type
  • 2.6.4 Epidemiology by Gender
  • 2.6.5 Epidemiology by Age Group
  • 2.6.6 Treated Patient Population
  • 2.6.7 Diagnosed Patient Population

3. Market Dynamics

• 3.1 Market Overview
• 3.2 Market Drivers
  • 3.2.1 Rising Disease Awareness and Diagnosis
  • 3.2.2 Increasing Adoption of Targeted Therapies
  • 3.2.3 Advancements in Neuromodulation Technologies
• 3.3 Market Restraints
  • 3.3.1 Underdiagnosis and Misdiagnosis
  • 3.3.2 High Treatment Costs
  • 3.3.3 Limited Availability of Approved Therapies
• 3.4 Market Opportunities
  • 3.4.1 Expansion of CGRP-Based Therapies
  • 3.4.2 Development of Novel Neuromodulation Devices
  • 3.4.3 Emerging Markets Expansion
• 3.5 Market Challenges
  • 3.5.1 Reimbursement Barriers
  • 3.5.2 Clinical Trial Recruitment Challenges
  • 3.5.3 Long-Term Treatment Compliance

4. Commercial & Market Access

• 4.1 Commercial Landscape Overview
• 4.2 Pricing Analysis
• 4.3 Reimbursement Scenario
• 4.4 Health Technology Assessment Trends
• 4.5 Patient Assistance Programs
• 4.6 Market Access Challenges
• 4.7 Stakeholder Analysis

5. Innovation & Pipeline Landscape

• 5.1 Innovation Trends
• 5.2 Emerging Therapeutic Targets
  • 5.2.1 CGRP Pathway
  • 5.2.2 PACAP Pathway
  • 5.2.3 Serotonin Receptor Targets
  • 5.2.4 Neuromodulation Approaches
• 5.3 Pipeline Landscape Overview
• 5.4 Pipeline Analysis by Clinical Phase
  • 5.4.1 Phase I
  • 5.4.2 Phase II
  • 5.4.3 Phase III
• 5.5 Pipeline Analysis by Mechanism of Action
• 5.6 Pipeline Analysis by Modality
  • 5.6.1 Small Molecules
  • 5.6.2 Monoclonal Antibodies
  • 5.6.3 Medical Devices
  • 5.6.4 Combination Therapies
• 5.7 Clinical Trial Landscape
  • 5.7.1 Ongoing Trials
  • 5.7.2 Completed Trials
  • 5.7.3 Trial Outcomes and Trends

6. Treatment Landscape

• 6.1 Current Treatment Paradigm
• 6.2 Acute Treatments
  • 6.2.1 Oxygen Therapy
  • 6.2.2 Triptans
  • 6.2.3 Other Acute Therapies
• 6.3 Preventive Treatments
  • 6.3.1 Calcium Channel Blockers
  • 6.3.2 Corticosteroids
  • 6.3.3 CGRP Monoclonal Antibodies
  • 6.3.4 Other Preventive Therapies
• 6.4 Neuromodulation Therapies
  • 6.4.1 Non-invasive Vagus Nerve Stimulation
  • 6.4.2 Sphenopalatine Ganglion Stimulation
  • 6.4.3 Deep Brain Stimulation
  • 6.4.4 Occipital Nerve Stimulation
• 6.5 Treatment Algorithm
• 6.6 Unmet Needs and Future Treatment Trends

7. Global Cluster Headache Treatment Landscape Report Size & Forecast

• 7.1 Global Market Size Analysis
• 7.2 Global Market Forecast
• 7.3 Market Forecast by Treatment Type
• 7.4 Market Forecast by Route of Administration
• 7.5 Market Forecast by End User
• 7.6 Market Forecast by Distribution Channel
• 7.7 Market Attractiveness Analysis

8. Global Cluster Headache Treatment Landscape Report Segmentation

• 8.1 By Treatment Type
  • 8.1.1 Acute Treatment
  • 8.1.2 Preventive Treatment
  • 8.1.3 Bridge Treatment
• 8.2 By Drug Class
  • 8.2.1 Triptans
  • 8.2.2 CGRP Monoclonal Antibodies
  • 8.2.3 Calcium Channel Blockers
  • 8.2.4 Corticosteroids
  • 8.2.5 Other Drug Classes
• 8.3 By Indication
  • 8.3.1 Episodic Cluster Headache
  • 8.3.2 Chronic Cluster Headache
• 8.4 By Route of Administration
  • 8.4.1 Oral
  • 8.4.2 Injectable
  • 8.4.3 Intranasal
• 8.5 By End User
  • 8.5.1 Hospitals
  • 8.5.2 Speciality Clinics
  • 8.5.3 Home Care Settings
• 8.6 By Distribution Channel
  • 8.6.1 Hospital Pharmacies
  • 8.6.2 Retail Pharmacies
  • 8.6.3 Online Pharmacies

9. Geographical Analysis (Regional Level)

• 9.1 North America
  • 9.1.1 Market Size & Growth
  • 9.1.2 Demand Drivers
  • 9.1.3 Regulatory Overview
  • 9.1.4 Competitive Intensity
• 9.2 Europe
  • 9.2.1 Market Size & Growth
  • 9.2.2 Demand Drivers
  • 9.2.3 Regulatory Overview
  • 9.2.4 Competitive Intensity
• 9.3 Asia-Pacific
  • 9.3.1 Market Size & Growth
  • 9.3.2 Demand Drivers
  • 9.3.3 Regulatory Overview
  • 9.3.4 Competitive Intensity
• 9.4 Latin America
  • 9.4.1 Market Size & Growth
  • 9.4.2 Demand Drivers
  • 9.4.3 Regulatory Overview
  • 9.4.4 Competitive Intensity
• 9.5 Middle East & Africa
  • 9.5.1 Market Size & Growth
  • 9.5.2 Demand Drivers
  • 9.5.3 Regulatory Overview
  • 9.5.4 Competitive Intensity

10. Key Countries Analysis

• 10.1 United States
• 10.2 Canada
• 10.3 Germany
• 10.4 United Kingdom
• 10.5 France
• 10.6 Italy
• 10.7 Spain
• 10.8 China
• 10.9 Japan
• 10.10 India
• 10.11 South Korea
• 10.12 Australia
• 10.13 Brazil
• 10.14 Mexico
• 10.15 Saudi Arabia
• 10.16 South Africa

11. Regulatory & Policy Landscape

• 11.1 Global Regulatory Overview
• 11.2 United States Regulatory Framework (FDA)
• 11.3 European Regulatory Framework (EMA)
• 11.4 Japan Regulatory Framework (PMDA)
• 11.5 India Regulatory Framework (CDSCO)
• 11.6 China Regulatory Framework (NMPA)
• 11.7 Drug Approval Pathways
• 11.8 Medical Device Approval Pathways
• 11.9 Reimbursement and Market Access Policies
• 11.10 Emerging Regulatory Trends

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Competitive Benchmarking
• 12.3 Product Portfolio Analysis
• 12.4 Pipeline Competitiveness
• 12.5 Strategic Collaborations and Partnerships
• 12.6 Licensing Agreements
• 12.7 Mergers and Acquisitions
• 12.8 Recent Developments

13. Company Profiles

• 13.1 Eli Lilly and Company
  • 13.1.1 Company Overview
  • 13.1.2 Approved Products for Cluster Headache and Related Neurology Indications
  • 13.1.3 Key Indications
  • 13.1.4 Pipeline Portfolio (Phase I/II/III)
  • 13.1.5 Recent Developments
  • 13.1.6 Strategic Outlook
• 13.2 electroCore, Inc.
  • 13.2.1 Company Overview
  • 13.2.2 Approved Products and Devices
  • 13.2.3 Key Indications
  • 13.2.4 Pipeline Portfolio
  • 13.2.5 Recent Developments
  • 13.2.6 Strategic Outlook
• 13.3 Pfizer Inc.
  • 13.3.1 Company Overview
  • 13.3.2 Approved Products
  • 13.3.3 Key Indications
  • 13.3.4 Pipeline Portfolio
  • 13.3.5 Recent Developments
  • 13.3.6 Strategic Outlook
• 13.4 GlaxoSmithKline plc
  • 13.4.1 Company Overview
  • 13.4.2 Approved Products
  • 13.4.3 Key Indications
  • 13.4.4 Pipeline Portfolio
  • 13.4.5 Recent Developments
  • 13.4.6 Strategic Outlook
• 13.5 Medtronic
  • 13.5.1 Company Overview
  • 13.5.2 Approved Devices
  • 13.5.3 Key Indications
  • 13.5.4 Pipeline Portfolio
  • 13.5.5 Recent Developments
  • 13.5.6 Strategic Outlook
• 13.6 Grunenthal GmbH
  • 13.6.1 Company Overview
  • 13.6.2 Approved Products
  • 13.6.3 Key Indications
  • 13.6.4 Pipeline Portfolio
  • 13.6.5 Recent Developments
  • 13.6.6 Strategic Outlook
• 13.7 Zosano Pharma Corp.
  • 13.7.1 Company Overview
  • 13.7.2 Approved Products
  • 13.7.3 Key Indications
  • 13.7.4 Pipeline Portfolio
  • 13.7.5 Recent Developments
  • 13.7.6 Strategic Outlook
• 13.8 Bausch Health Companies Inc.
  • 13.8.1 Company Overview
  • 13.8.2 Approved Products
  • 13.8.3 Key Indications
  • 13.8.4 Pipeline Portfolio
  • 13.8.5 Recent Developments
  • 13.8.6 Strategic Outlook
• 13.9 Viatris Inc.
  • 13.9.1 Company Overview
  • 13.9.2 Approved Products
  • 13.9.3 Key Indications
  • 13.9.4 Pipeline Portfolio
  • 13.9.5 Recent Developments
  • 13.9.6 Strategic Outlook
• 13.10 Autonomic Technologies Inc.
  • 13.10.1 Company Overview
  • 13.10.2 Approved Products and Devices
  • 13.10.3 Key Indications
  • 13.10.4 Pipeline Portfolio
  • 13.10.5 Recent Developments
  • 13.10.6 Strategic Outlook

14. Future Outlook

• 14.1 Future Market Trends
• 14.2 Emerging Technologies
• 14.3 Pipeline Commercialization Outlook
• 14.4 Competitive Evolution
• 14.5 Investment Opportunities
• 14.6 Scenario Analysis
• 14.7 Long-Term Market Forecast

15. Methodology

• 15.1 Research Objectives
• 15.2 Research Design
• 15.3 Secondary Research Sources
• 15.4 Primary Research Methodology
• 15.5 Market Size Estimation
• 15.6 Forecasting Methodology
• 15.7 Data Validation and Triangulation
• 15.8 Assumptions and Limitations
• 15.9 Abbreviations and Definitions